Neutral endopeptidase inhibitors blunt kidney fibrosis by reducing myofibroblast formation

Autor: Jacques M.G.J. Duijs, Dania Reiche, Jerzy Adamski, Ton J. Rabelink, Cornelia Prehn, Jennifer Veth, Roel Bijkerk, Marina A. Aleksinskaya, Jo G. R. De Mey, Bettina Husen, Anton Jan van Zonneveld

Publikováno v: Clinical Science, 133(2), 239-252. Portland Press Ltd.
Bijkerk, R, Aleksinskaya, M A, Duijs, J M G J, Veth, J, Husen, B, Reiche, D, Prehn, C, Adamski, J, Rabelink, T J, De Mey, J G R & van Zonneveld, A J 2019, ' Neutral endopeptidase inhibitors blunt kidney fibrosis by reducing myofibroblast formation ', Clinical Science, vol. 133, no. 2, pp. 239-252 . https://doi.org/10.1042/CS20180882

Kidney fibrosis is the common pathophysiological mechanism in end-stage renal disease characterized by excessive accumulation of myofibroblast-derived extracellular matrix. Natriuretic peptides have been demonstrated to have cyclic guanosine monophos

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81faab805c728d406474cc71f5af6e3f
https://doi.org/10.1042/cs20180882

Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice

Autor: Mark A. Yorek, Randy H. Kardon, Alexander Obrosov, Craig John Gerard, Bao Lu, Matthew S. Yorek

Publikováno v: Journal of Neuropathology and Experimental Neurology

Previously we demonstrated that a vasopeptidase inhibitor of angiotensin converting enzyme and neutral endopeptidase (NEP), a protease that degrades vaso- and neuro-active peptides, improves neural function in diabetic rodent models. The purpose of t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2d6a8badcf5e8eadc4bddb6999b69e5
https://doi.org/10.1093/jnen/nlw083

Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome

Autor: Yoav Eizenberg, Yehonatan Sharabi, Zehava Shabtai, Ehud Grossman, Edna Peleg

Publikováno v: Journal of the American Society of Hypertension. 8:227-231

The antihypertensive treatment in patients with metabolic syndrome is unclear. We therefore used a rat model of the metabolic syndrome and compared the effects of enalapril, an angiotensin-converting-enzyme inhibitor, with candoxatril, a neutral endo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccec0ad23bd183ca321ab24b2d6ea717
https://doi.org/10.1016/j.jash.2014.01.006

Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats

Autor: Christine L. Oltman, Travis L. Kleinschmidt, Eric P. Davidson, Brian L. Dake, Lawrence J. Coppey, Mark A. Yorek

Publikováno v: European Journal of Pharmacology. 650:556-562

We have previously shown that treating streptozotocin-induced diabetic rats, an animal model of type 1 diabetes, with Ilepatril (an inhibitor of neutral endopeptidase and angiotensin converting enzyme (ACE)) improves vascular and neural function. In

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::829fb360dda4a62b145c56c497e79155
https://doi.org/10.1016/j.ejphar.2010.10.047

Role of neprilysin inhibitors in cardiovascular Disease-A short review

Autor: K. A Jayashree

Publikováno v: Research Journal of Pharmacy and Technology. 11:2111

Cardiovascular diseases (CVD) continue to represent the major cause of death, morbidity and healthcare expenditure worldwide. Hypertension and heart failure, the most important cardiovascular disease entities, are associated with imbalance in neuroho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d7311fb4beb8d6cc0fd10a4e6d703a4d
https://doi.org/10.5958/0974-360x.2018.00391.8